Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci145 in PIK3CA-mutated Solid Tumors
NCT07407504Phase 1Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GenSci145 in solid tumor and breast cancer, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Treatment-Emergent Adverse Events at 30 days and Dose Limiting Toxicities at 28 days. Started Apr 2026; status: recruiting.
02
Drugs
GenSci145
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT07407504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07407504.